Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CVKD 
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/24/2026: CVKD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35
1 Year Target Price $35
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.69M USD | Price to earnings Ratio - | 1Y Target Price 35 |
Price to earnings Ratio - | 1Y Target Price 35 | ||
Volume (30-day avg) 2 | Beta 1.21 | 52 Weeks Range 4.91 - 22.90 | Updated Date 02/24/2026 |
52 Weeks Range 4.91 - 22.90 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -209.23% | Return on Equity (TTM) -468.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24683190 | Price to Sales(TTM) - |
Enterprise Value 24683190 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.21 | Shares Outstanding 2338127 | Shares Floating 1611478 |
Shares Outstanding 2338127 | Shares Floating 1611478 | ||
Percent Insiders 22.37 | Percent Institutions 8.64 |
Upturn AI SWOT
Cadrenal Therapeutics, Inc. Common Stock
Company Overview
History and Background
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for rare cardiovascular diseases. The company was founded to address unmet medical needs in conditions like pulmonary arterial hypertension (PAH). Significant milestones include progress in clinical trials for their lead drug candidate.
Core Business Areas
- Cardiovascular Disease Therapeutics: Development of novel drug candidates for the treatment of rare and serious cardiovascular diseases, with a current primary focus on pulmonary arterial hypertension (PAH).
Leadership and Structure
Cadrenal Therapeutics, Inc. is led by a management team with experience in drug development and the biopharmaceutical industry. The organizational structure is typical of a clinical-stage biotech company, emphasizing research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Competitors: United Therapeutics (UTHR),Bayer (BAYRY),Pfizer (PFE)
- Description: A therapeutic agent undergoing clinical trials for the treatment of Pulmonary Arterial Hypertension (PAH). Market share data is not yet applicable as it is in clinical development. Competitors in the PAH market include companies with approved therapies such as United Therapeutics, Bayer, and Pfizer.
- Market Share:
- Number of Users:
- Product Name: Lead Drug Candidate for PAH (Name not publicly disclosed in detail)
- Revenue:
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the rare disease and cardiovascular segments, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. However, it also offers the potential for high rewards due to unmet medical needs and premium pricing for successful therapies.
Positioning
Cadrenal Therapeutics is positioned as a developer of novel therapies for rare cardiovascular diseases. Its competitive advantage lies in its specialized focus on specific unmet needs within the PAH market and its targeted therapeutic approach.
Total Addressable Market (TAM)
The global market for Pulmonary Arterial Hypertension (PAH) therapeutics is estimated to be in the billions of dollars and is projected to grow. Cadrenal Therapeutics aims to capture a significant portion of this market with its innovative treatment if clinical trials are successful and regulatory approval is obtained.
Upturn SWOT Analysis
Strengths
- Focus on rare cardiovascular diseases with significant unmet needs.
- Experienced management team in drug development.
- Potentially novel therapeutic mechanism of action.
Weaknesses
- Clinical-stage company with no approved products yet.
- High dependence on successful clinical trial outcomes.
- Limited financial resources compared to established pharmaceutical giants.
- Potential for dilution through future fundraising.
Opportunities
- Growing market for rare disease treatments.
- Potential for strategic partnerships or acquisitions.
- Advancements in understanding cardiovascular disease pathways.
- Expedited regulatory pathways for rare disease drugs.
Threats
- Failure in clinical trials.
- Regulatory hurdles and delays.
- Competition from existing and emerging therapies.
- Patent expirations of competitor drugs affecting market dynamics.
- Changes in healthcare reimbursement policies.
Competitors and Market Share
Key Competitors
- United Therapeutics (UTHR)
- Bayer AG (BAYRY)
- Pfizer Inc. (PFE)
- Gilead Sciences, Inc. (GILD)
Competitive Landscape
Cadrenal Therapeutics faces competition from established pharmaceutical companies with approved PAH treatments. Its advantage lies in its focused approach to potentially address specific patient populations or mechanisms not fully covered by existing therapies. However, its lack of an approved product means it currently holds no market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Cadrenal Therapeutics has been characterized by pipeline advancement and strategic fundraising rather than revenue-based growth. This growth is measured by progress in clinical development phases and the expansion of its scientific and operational capabilities.
Future Projections: Future growth projections are contingent upon the successful development and commercialization of its lead drug candidate. Analyst estimates, if available, would focus on potential peak sales and market penetration post-approval.
Recent Initiatives: Recent initiatives likely involve progressing their lead drug candidate through clinical trials, building out their scientific advisory board, and securing necessary funding for ongoing development.
Summary
Cadrenal Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company focused on rare cardiovascular diseases, particularly PAH. Its strengths lie in its specialized focus and potential for innovative therapies. However, it faces significant risks inherent in drug development, including clinical trial failures and regulatory challenges. The company's success hinges on its ability to navigate these risks and bring its lead candidate to market, while managing its financial resources effectively.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (e.g., SEC filings)
- Industry research reports
- Financial news outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information is based on publicly available data and AI analysis, which may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cadrenal Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2023-01-20 | Chairman & CEO Mr. Quang X. Pham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.cadrenal.com |
Full time employees 4 | Website https://www.cadrenal.com | ||
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.